Compare ALLO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLO | ACRS |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 529.9M |
| IPO Year | 2018 | 2015 |
| Metric | ALLO | ACRS |
|---|---|---|
| Price | $0.76 | $3.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $9.00 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 11.2M | 2.7M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.09 | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $2.34 |
| 52 Week High | $4.46 | $6.60 |
| Indicator | ALLO | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 21.26 | 37.00 |
| Support Level | N/A | $3.24 |
| Resistance Level | $2.25 | $3.44 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 0.42 | 9.38 |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.